ORR—26% (CR 1/54, CRi 6/54, MLFS, 6/54, PR 1/54)mDoR—20 wks-pts not exposed FLT3 inhibitor, longer (p = 0.05)-pts not received SCT, longer (p = 0.01)mOS—22 wks→ midostaurin with AZA, effective and safe in AML and high-risk MDS pts. This evidence concerns the gene FLT3 and myelodysplastic syndrome.